Did not meet the criteria to continue to second stage, sounds negative to a layman.Evaluation will continue for the first stage patients so still hope here.Readout in 2nd half 2023, so most likely the share price will be bottom bouncing for a whole year, and the result may still be underwhelming.
The stock is dead for practical purposes.
Revisit in 12 months time.
- Forums
- ASX - By Stock
- KZA
- Ann: GBM Agile Update
Ann: GBM Agile Update, page-58
-
-
- There are more pages in this discussion • 121 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)